Amylyx Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 12 analysts polled by S&P Global, Amylyx Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $23.4. The average 1-year stock price forecast is 55.48% higher than the current stock price, while the lowest is $19 (+26.25%) and the highest is $34 (+125.91%).

Price Target: $23.4 (+55.48%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$19	$23.4	$21.5	$34
Change	+26.25%	+55.48%	+42.86%	+125.91%

* Price targets were last updated on May 16, 2026.

Analyst Ratings

The average analyst rating for Amylyx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	10	10	10	11	11	11
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Rami Katkhuda LifeSci Capital	LifeSci Capital	Buy Maintains $24	Buy	Maintains	$24	+59.47%	May 16, 2026
Graig Suvannavejh Mizuho Securities	Mizuho Securities	Buy Reiterates $21	Buy	Reiterates	$21	+39.53%	May 11, 2026
Seamus Fernandez Guggenheim	Guggenheim	Buy Reiterates $30	Buy	Reiterates	$30	+99.34%	May 11, 2026
Andrew Fein H.C. Wainwright	H.C. Wainwright	Buy Maintains $34	Buy	Maintains	$34	+125.91%	May 8, 2026
Dina Ramadane Bank of America Securities	Bank of America Securities	Buy Reiterates $22	Buy	Reiterates	$22	+46.18%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

40.22M

EPS This Year

-1.38

from -1.53

EPS Next Year

-1.27

from -1.38

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	285.00K	22.23M	380.79M	87.37M	-	-
Gross Profit	-43.76M	-74.21M	227.16M	-141.35M	-90.40M	-
Gross Margin	-15,352.63%	-333.84%	59.66%	-161.78%	-	-
Operating Income	-82.69M	-201.34M	38.80M	-255.68M	-153.29M	-173.34M
Net Income	-87.93M	-198.38M	49.27M	-301.74M	-144.74M	-167.12M
EPS	-	-	-	-	-1.53	-1.38
Free Cash Flow	-46.85M	-105.35M	38.36M	-134.74M	-66.99M	-152.43M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-1.05
Avg	-1.38
Low	-1.59

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-